Board Change • May 21
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Vice Chairman Jonathan Allis was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Feb 13
EXACT Therapeutics AS, Annual General Meeting, Jun 12, 2026 EXACT Therapeutics AS, Annual General Meeting, Jun 12, 2026. Announcement • Jun 24
EXACT Therapeutics Announces First Patient Dosed in Phase 2 Trial in Patients with Locally Advanced Pancreatic Cancer EXACT Therapeutics announced first patient dosed in its ENACT trial. The trial is a multi-centre, open-label Phase 2 clinical trial testing the safety and efficacy of Acoustic Cluster Therapy (ACT®) in combination with standard of care (modified FOLFIRINOX chemotherapy) in first line patients with borderline resectable or unresectable locally advanced pancreatic cancer. Dosing of the first patient in the Phase 2 trial follows the announcement of positive final efficacy and safety data in the Phase 1 trial in patients with liver metastases of colorectal origin. The Phase 2 trial will enroll up to 25 patients in the U.S., U.K. and Europe, and has the ClinicalTrials.gov Identification: NCT06850623. Announcement • Jun 13
Exact Therapeutics AS Approves Election of Following Nomination Committee Composition EXACT Therapeutics AS at its AGM held on June 13, 2025 approved to elect the following Nomination Committee composition: Svein Kvåle (Chair), Birgitte Gangmark Villmo, Sir William Castell. Announcement • May 20
EXACT Therapeutics Announces Positive Final Results in Phase 1 ACTIVATE Trial in Liver Metastases from Colorectal Cancer EXACT Therapeutics AS announced positive final results in Phase 1 ACTIVATE trial in liver metastases from colorectal cancer. These results indicate that EXACT Therapeutics' Acoustic Cluster Therapy (ACT®?) significantly enhances the local effect of chemotherapy; In the patients who had a response to chemotherapy, ACT-treated tumours showed a significantly greater reduction in diameter compared to control tumours (-29% vs. -7%, p. The final results affirm the previously reported positive ACTIVATE outcomes and indicate the significant added efficacy of ACT with chemotherapy compared with chemotherapy alone. Among patients who responded to chemotherapy, tumor shrinkage was significantly greater with ACT and chemotherapy compared to chemotherapy alone in the same individuals (29% vs. 7%, p<0.05). Announcement • Jan 29
Cordance Medical and EXACT Therapeutics Announces Early Encouraging Data in Brain Cancer Mice Model Cordance Medical and EXACT Therapeutics announced initial positive results indicating more than a doubling (+127-145%) of the uptake of a radiopharmaceutical in brain tumors of mice inoculated with glioblastoma cancer cells, one of the most aggressive and hard-to-treat brain cancers. The increased uptake resulted from combining Exact Therapeutics' proprietary Acoustic Cluster Therapy (ACT®) with a device designed by Cordance Medical to deliver ultrasound energy non-invasively into the brain. The studies were performed at The Arctic University of Norway and University Hospital North-Norway in Tromsø by Dr. Mathias Kranz. The combination of ACT® and the device can be used in a wide range of brain diseases to potentially access large regions of the brain. The combination can stimulate bioeffects including increasing the uptake of therapeutic agents and temporarily making the blood-brain barrier more permeable in these regions. The combination of ACT® and the device may be utilized for both diagnostic and targeted therapeutic brain applications. Further experiments are ongoing to expand the early data, and the results will be submitted for publication in scientific journals. Announcement • Jan 28
Exact Therapeutics and Cordance Medical Announce Early Encouraging Data in Brain Cancer Mice Model EXACT Therapeutics and Cordance Medical announced initial positive results indicating more than a doubling (+127-145%) of the uptake of a radiopharmaceutical in brain tumors of mice inoculated with glioblastoma cancer cells, one of the most aggressive and hard-to-treat brain cancers. The increased uptake resulted from combining Exact Therapeutics’ proprietary Acoustic Cluster Therapy (ACT®) with a device designed by Cordance Medical to deliver ultrasound energy non-invasively into the brain. The studies were performed at The Arctic University of Norway and the University Hospital of North-Norway in Tromsø by Dr. Mathias Kranz. The combination of ACT and the device may offer potential applications across a wide range of brain diseases, by enabling therapeutic access to large brain regions. The combined technologies can induce bioeffects, such as temporarily increasing blood-brain barrier permeability in targeted regions and increasing the uptake of therapeutic agents. ACT and the device may be utilized for both diagnostic and targeted therapeutic brain applications. Further experiments are ongoing to expand the early data, and the results will be submitted for publication in scientific journals. Announcement • Jan 08
EXACT Therapeutics AS, Annual General Meeting, Jun 13, 2025 EXACT Therapeutics AS, Annual General Meeting, Jun 13, 2025. Announcement • Aug 07
EXACT Therapeutics AS Announces Full Focus on Phase 2 Pancreatic Cancer Trial EXACT Therapeutics AS announced that it will now be focusing all clinical efforts on the upcoming Phase 2 ENACT trial in locally advanced pancreatic cancer and is stopping recruitment in the Phase 1 ACTIVATE clinical trial in cancer patients with liver metastases of colorectal origin. Previously, the Phase 1 ACTIVATE trial reported positive interim efficacy and safety data. The enrolled patients will be followed through the planned follow-up. The final results from the ACTIVATE Phase 1 trial (11 patients) will be reported after completion of independent blinded review, expected early 2025. So far, there has been no change to the previously reported excellent safety profile of PS101 in the ACTIVATE trial. New Risk • Apr 15
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 17% per year over the past 5 years. Revenue is less than US$1m (kr453k revenue, or US$42k). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (6.9% increase in shares outstanding). Market cap is less than US$100m (€16.6m market cap, or US$17.6m). New Risk • Dec 22
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 17% per year over the past 5 years. Revenue is less than US$1m (kr453k revenue, or US$44k). Minor Risks Share price has been volatile over the past 3 months (7.8% average weekly change). Shareholders have been diluted in the past year (6.9% increase in shares outstanding). Market cap is less than US$100m (€31.4m market cap, or US$34.5m). Announcement • Dec 02
EXACT Therapeutics AS has completed a Follow-on Equity Offering in the amount of NOK 24.999996 million. EXACT Therapeutics AS has completed a Follow-on Equity Offering in the amount of NOK 24.999996 million.
Security Name: Ordinarey Shares
Security Type: Common Stock
Securities Offered: 2,083,333
Price\Range: NOK 12
Transaction Features: Subsequent Direct Listing New Risk • Sep 29
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr40m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr40m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 17% per year over the past 5 years. Revenue is less than US$1m (kr453k revenue, or US$42k). Minor Risk Market cap is less than US$100m (€40.9m market cap, or US$43.3m). Announcement • Sep 28
EXACT Therapeutics AS Announces Appointment of Caspar Foghsgaard as SVP Commercial & Business Development Effective 1 November 2023 EXACT Therapeutics AS announced that Caspar Foghsgaard is joining the company as Senior Vice President Commercial and Business Development, effective 1 November 2023. Caspar Foghsgaard joins Exact Therapeutics from Nykode Therapeutics where his latest role was as Sr. Director Special Projects and part of the extended leadership team. He joined Nykode in 2018 and have been closely involved in Nykode’s transformation from a small biotech to a leading company at Oslo Stock Exchange. Prior to his role as Sr. Director Special Projects, he was heading Nykode’s business development activities as Director Business Development. Other previous employers include Arcus where he was responsible for business development in the spirits division and part of the divisional management, and Elopak as Program Director Strategy. In addition, he has held various business development and strategy positions including with Novozymes in Denmark, U.S. and U.K. Announcement • Sep 27
EXACT Therapeutics Announces Positive Clinical Results from the Activate Phase I Dose Escalation EXACT THERAPEUTICS AS announced positive safety and anticancer activity results from the dose escalation part of the ACTIVATE trial. The data will be presented at a medical conference in early 2024. Eight patients were enrolled into the dose escalation part of the study. The results suggest that ACT treatment in combination with FOLFOX or FOLFIRI is well tolerated without unexpected acute or delayed side effects of the ACT treatment or worsening of side effects of the chemotherapy. Positive anticancer responses have been seen in all but one of the evaluable patients in this hard-to-treat patient population, showing that the ACT treatment can enhance anticancer response to Standard of Care chemotherapy. Announcement • Aug 08
EXACT Therapeutics Completes the Dose Escalation Part of ACTIVATE Study EXACT Therapeutics AS announced that the dose escalation part of the ACTIVATE study is completed. This part of the study enrolled 8 patients, with 6 patients eligible for evaluation. The study is conducted at the Institute of Cancer Research (ICR), Royal Marsden Hospital, London with Professor Udai Banerji as the principal investigator. A presentation of the safety and efficacy findings will be released when the full results are available. The study Trial Monitoring Committee reviewed the safety data from the dose escalation and approved initiation of the dose expansion part of the ACTIVate study. The dose expansion is designed to determine the dose level for further development of ACT and expand the safety and efficacy data with 12 to 20 patients with metastatic colorectal cancer. All necessary approvals have already been awarded by the UK MHRA, as reported on July 31, and enrolment will now commence. Announcement • Aug 01
EXACT Therapeutics AS Receives Regulatory Approval to Start the Dose Expansion Part of ACTIVATE Study EXACT THERAPEUTICS AS announced that the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) has awarded all necessary approvals to start the dose expansion part of the ACTIVATE study. This part of the ACTIVATE study is designed to determine the dose level for further development and expand the safety and efficacy data of ACT in patients with metastatic colorectal cancer. 12 to 20 patients are planned to be enrolled into the dose expansion part of the ACTIVATE study. Announcement • Jun 10
EXACT Therapeutics AS Announces Management Changes EXACT Therapeutics AS at its Annual General Meeting held on June 9, 2023, announced Jean-Michel Cosséry is not seeking re-election as board member. In accordance with the Nomination Committee's proposal, the following Nomination Committee composition was made: Leiv Askvig (Chair); Dag Strømme; Birgitte Gangmark Villmo and Svein Kvåle. Announcement • Feb 03
Exact Therapeutics Receives Regulatory Approval to Reopen the Activate Clinical Trial On February 2, 2023, EXACT Therapeutics AS announced that the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) has approved reopening of the clinical phase I ACTIVATE trial. As communicated in a press release of 8 March 2022, EXACT-Tx received a request from the MHRA for an additional submission and approval of medical device documentation associated to the protocol amendment filed with the ACTIVATE phase I clinical trial. EXACT-Tx responded to the request and has now received MHRA’s approval on both the medical device documentation and the amended protocol. The approvals were made without objections. For EXACT-Tx, this mean that the ACTIVATE phase I trial will be reopened and additional patients will be recruited for the trial. So far, there have been seven patients enrolled in the study with five patients’ data being evaluable for the study endpoints. Several valuable and encouraging insights have been gained from this first cohort of treated patients. Announcement • Dec 22
Norwegian Research Council Awards EXACT Therapeutics AS Exact-Tx NOK 16 Million to Support the Research of Immunotherapy Responses in Solid Tumours with Acoustic Cluster Therapy EXACT Therapeutics AS announced that the Norwegian Research Council has awarded EXACT-Tx NOK 16 million to support the research of immunotherapy responses in solid tumours with Acoustic Cluster Therapy (ACT®). The research project is in collaboration with three renowned academic partners; Norwegian University of Science and Technology (NTNU)(Norway), Institute of Cancer Research (ICR)/Royal Marsden Hospital (UK) and Translational Genomics Research Institute (TGen)(USA). ACT® is currently in clinical development for combination with standard of care chemotherapeutic agents. Several preclinical studies have shown that ACT® can provide a remarkable increase in the therapeutic efficacy of this class of cancer drugs. The aim of the awarded research project is preclinical development of ACT® combined with immuno-oncology (IO) agents for treatment of solid cancers. IO-agents, and especially checkpoint inhibitors, represent an emerging and important class of cancer drugs that can provide long-term response in some cancer patients. Unfortunately, only a minority of patients respond to immunotherapy and the efficacy may partly be hampered by insufficient delivery to target tissues. Research into novel drug delivery systems is therefore of great importance. The awarded research project comprises six preclinical work packages investigating ACT® with checkpoint inhibitors for treatment of breast cancer, colon cancer and pancreatic cancer. The primary objective is to demonstrate preclinical proof of concept for treatment of one or more of these diseases. The project end point is performing a clinical trial within the IO segment. Board Change • Nov 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Chair of the Board Anders Wold was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Sep 17
EXACT Therapeutics AS Announces Appointment of Amir Snapir as Chief Medical Officer, Effective 21 September 2022 EXACT Therapeutics AS announced the appointment of Dr. Amir Snapir as Chief Medical Officer (CMO), effective 21 September 2022. Dr. Snapir has a PhD from the University of Turku, Finland and an MD from the University of Tel Aviv, Israel. He has extensive experience in global clinical development of novel therapeutics, from early clinical translation to marketing authorisation, combined with extensive international regulatory experience. Dr. Snapir also has years of experience in business collaborations, alliances and product co-developments. Dr. Snapir comes from the position as CMO of PCI Biotech where he was responsible for the clinical development of drug-device combination product candidates. From 2007 to 2020 he held various positions at Orion Pharma, Espoo, Finland, spanning from leader of clinical pharmacogenomics to clinical development leader in Oncology. Dr. Snapir is the author of numerous scientific publications. Announcement • Sep 01
EXACT Therapeutics AS Appoints John Edminson as Chief Financial Officer, Effective 1 October 2022 EXACT Therapeutics AS announced the appointment of John Edminson as Chief Financial Officer, effective 1 October 2022. John is a graduate from the Norwegian School of Economics with a Master in Auditing and Accounting and he built his career foundations working in audit at KPMG, which included 1.5 years in Boston, USA. He subsequently gained experience in both finance and operations in a variety of companies, including Telenor, ACNielsen, and Kistefos, before taking on CFO roles in PatientSky and Questback. Announcement • Jun 09
EXACT Therapeutics as Announces Board Changes EXACT Therapeutics AS announced that Anders Wold, Board Director since December 2021, has been appointed Chair of the Board, with immediate effect. Anders Wold started his career in the field of medical ultrasound in 1984 as he joined the start-up Vingmed which was acquired in 1998 by GE Healthcare. He has nearly forty years of leadership experience in the healthcare and ultrasound industry including President and CEO of GE Healthcare Clinical Care Solutions. The current Executive Chair of the Board, Dr. Masha Strømme will assume the role of Vice-Chair of the Board. Sir William Castell, current Vice-Chair of the Board, will assume the role of Director of the Board alongside Dr. Jean-Michel Cosséry and Ann-Tove Kongsnes. Dr. Aitana Peire did not seek re-election and on behalf of the shareholders, the Board of Directors would like to thank her for her support and excellent contribution. Announcement • May 20
EXACT Therapeutics AS Announces Resignation of Dr. Jean-Claude Provost as Board Member EXACT Therapeutics AS announced that its Board Member, Dr. Jean-Claude Provost will step down with immediate effect. Dr. Provost has taken on a new role as interim CMO of Lantheus Holdings. As this could represent a conflict of interest with his current Board appointment to EXACT-Tx, the Company and Dr. Provost have agreed that he will resign from the Board of Directors with immediate effect. The Nomination Committee is recommending that he is not replaced at the AGM in June. Board Change • Apr 28
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Director Anders Wold was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Mar 29
EXACT Therapeutics AS Appoints Per Walday as Chief Executive Officer EXACT Therapeutics AS announced that its Board of Directors has appointed Dr. Per Walday as Chief Executive Officer (CEO). A successful senior executive in the healthcare industry, Per has experience from research to commercialization of therapeutics and medical devices globally, including drug-device combination within the field of oncology. As CEO of PCI Biotech, Per built an effective organization that progressed the platform technology into a pipeline of assets including in late stage clinical programs through FDA and EMA regulatory paths. Prior to this, Per spent almost two decades with Nycomed Imaging and GE Healthcare based in Norway where, as Global Head Project Management, he was responsible for all development programs of new pharmaceutical products. Announcement • Mar 10
EXACT Therapeutics AS Announces Clinical Trial Update EXACT THERAPEUTICS AS provided an update regarding the phase I ACTIVATE study. As reported in Fourth Quarter 2021, EXACT-Tx filed a protocol amendment regarding its ACTIVATE phase I clinical trial with the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA). This week the MHRA issued a response to EXACT-Tx requiring an additional submission and approval of documentation regarding the protocol amendment. The Company expects that meeting this requirement which is specifically focused on the Ultrasound system used in combination with PS101, from the regulator will impact the timing of additional patient recruitment. So far, there have been seven patients enrolled in the study with five patients' data evaluable to date for dose limiting toxicity. A number of valuable and encouraging insights have been gained from this first cohort of treated patients. Executive Departure • Dec 06
Director Hans Klouman has left the company On the 3rd of December, Hans Klouman's tenure as Director ended. As of September 2021, Hans still personally held 399.75k shares (€815k worth at the time). A total of 2 executives have left over the last 12 months. The current median tenure of the management team is less than a year, which is considered inexperienced in the Simply Wall St Risk Model. Recent Insider Transactions • Jun 12
Deputy Chairperson recently bought €21k worth of stock On the 4th of June, William Castell bought around 10k shares on-market at roughly €2.06 per share. This was the largest purchase by an insider in the last 3 months. This was William's only on-market trade for the last 12 months. Announcement • May 29
EXACT Therapeutics AS Announces Clinical Trial Update EXACT Therapeutics AS provided an update regarding the ongoing phase I ACTIVATE study. Enrolment of patients in the study at the Royal Marsden Hospital in London has been adversely impacted through the Covid-19 pandemic period. There have been seven patients enrolled in the study with five patients’ data evaluable to date. A number of valuable and encouraging insights have been gained from this first cohort of treated patients, particularly with respect to application of ultrasound. In addition, as the organisation has expanded with appointment of experienced senior executives, focus has increased on improving quality management and internal governance processes. As a consequence, robust internal governance processes have been developed and implemented. In parallel, a protocol amendment is planned with a consequent impact on patient enrolment, which is anticipated to restart in fourth quarter 2021. 
